Headlines about Crispr Therapeutics (NASDAQ:CRSP) have been trending somewhat positive on Sunday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Crispr Therapeutics earned a daily sentiment score of 0.09 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.4163262792953 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
A number of equities analysts have issued reports on the company. Barclays reiterated a “buy” rating and set a $29.00 target price on shares of Crispr Therapeutics in a report on Friday, September 8th. SunTrust Banks restated a “hold” rating and issued a $16.00 price objective on shares of Crispr Therapeutics in a report on Friday, November 10th. Chardan Capital restated a “buy” rating on shares of Crispr Therapeutics in a report on Monday, August 14th. Cann restated a “hold” rating on shares of Crispr Therapeutics in a report on Thursday, November 9th. Finally, BidaskClub cut Crispr Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Crispr Therapeutics currently has an average rating of “Hold” and an average price target of $22.38.
Crispr Therapeutics (NASDAQ:CRSP) opened at $19.12 on Friday. Crispr Therapeutics has a 1-year low of $11.63 and a 1-year high of $25.00.
In other Crispr Therapeutics news, Director Thomas Woiwode sold 1,700 shares of the firm’s stock in a transaction that occurred on Friday, November 24th. The shares were sold at an average price of $20.21, for a total transaction of $34,357.00. Following the completion of the sale, the director now directly owns 8,218 shares in the company, valued at $166,085.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Rodger Novak sold 18,470 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $20.76, for a total transaction of $383,437.20. Following the sale, the chief executive officer now owns 1,148,007 shares of the company’s stock, valued at $23,832,625.32. The disclosure for this sale can be found here. Insiders have sold 20,370 shares of company stock valued at $421,842 in the last quarter. 39.98% of the stock is currently owned by corporate insiders.
Crispr Therapeutics Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
What are top analysts saying about Crispr Therapeutics AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Crispr Therapeutics AG and related companies.